Trial Profile
A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8266
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 8266 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record